Modifying CV risk by managing diabetes - PACE-CME

Modifying CV risk by managing diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
AHA 2024
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD